AstraZeneca's aldosterone synthase inhibitor baxdrostat reduced blood pressure by 14 mmHg over 12 weeks, the pharma has said ...
Novel Aldosterone Synthase Inhibitor Lorundrostat Shows Promise for Uncontrolled Hypertension in CKD
A new aldosterone synthase inhibitor added to SGLT2 inhibitors reduces uncontrolled blood pressure in patients with chronic kidney disease, according to the results of a phase 2 trial.
The combination therapy improved LVEF, quality of life, clinical outcomes, and more, but implementation questions remain.
As of Monday, November 10, Mineralys Therapeutics, Inc.’s MLYS share price has surged by 8.40%, which has investors questioning if this is right time to sell.
Combined capital will support the ongoing Phase 2a clinical trial of procizumab in cardiogenic shockSeries C round was supported by both existing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback